Modern view on treatment of chronic diffuse telogenous alopecia in men
O.Yu. Olisova, A.A. Lepyokhova
Sechenov University, Moscow
Androgenetic alopecia (AGA) occurs in 80% of men and 40% of women and is characterized by a gradual thinning of terminal hair, turning them into vellus and further loss. With AGA, there is a progressive shortening of the anagen phase, prolongation of the post-exogenous phase of the telogen (latent phase of the kenogen) and, finally, miniaturization of the hair follicle.
Aim: to study the efficacy of Neoptide Men lotion in hair loss in patients with AGA.
Patients and Methods: there were 30 men aged from 32 to 58 years with a diagnosis of AGA III–V degree on the Hamilton-Norwood scale under our observation. Parietal and occipital areas were photographed with a 200-fold and 60-fold magnification for each patient. The evaluation criteria were: the amount of vellus; thickness of hair — percentage of thin (40–60 microns), medium (60–80 microns) and thick (more than 80 microns); percentage of single, double, triple follicular units, the amount of yellow dots, percentage of perifollicular inflammation. The Neoptide Men lotion were administered once a day for 6 months.
Results: after 6 months of treatment, a decrease in the percentage of fine hair (31% and 25%), an increase in the percentage of medium (39% and 43%) and thick hair (30% and 35%) in the parietal and occipital zones, respectively. The ratio of single follicular units was 1:1, anisotrichosis and the amount of yellow dots in the frontal zone — 9.6% and 1%, respectively. The percentage of perifollicular inflammation was 15%. No side effects (including allergic reactions) were observed with the use of the Neoptide Men lotion.
Conclusion: Neoptide Men lotion for men is an effective and safe treatment for AGA III–IV degree.
For citation: Olisova O.Yu., Lepyokhova A.A. Modern view on treatment of chronic diffuse telogenous alopecia in men // RMJ. Medical Review. 2018. № 5. P. 47–51.
References
1. Tsuboi R., Arano O., Nishikawa T. et al. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men // J Dermatol. 2009. Vol. 36 (8). P.437–446.
2. Blume-Peytavi U., Blumeyer A., Tosti A. et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents // Br J Dermatol. 2011. Vol. 164 (1). P.5–15.
3. Inui S., Itami S. Androgen actions on the human hair follicle: perspectives // Exp Dermatol. 2013. Vol. 22 (3). P.168–171.
4. Heilmann-Heimbach S., Hochfeld L. M., Paus R., Nöthen M. M. Hunting the genes in male-pattern alopecia: how important are they, how close are we and what will they tell us? // Exp Dermatol. 2016. Vol. 25 (4). P.251–257.
5. Cela E., Robertson C., Rush K. et al. Prevalence of polycystic ovaries in women with androgenic alopecia // Eur J Endocrinol. 2003. Vol. 149 (5). P.439–442.
6. Blumeyer A., Tosti A., Messenger A. et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men // J Dtsch Dermatol Ges. 2011. Vol. 9. Suppl. 6. P.S1–57.
7. Bhamla S. A., Dhurat R. S., Saraogi P. P. Is Trichoscopy a Reliable Tool to Diagnose Early Female Pattern Hair Loss? // Int J Trichology. 2013. Vol. 5 (3). P.121–125.
8. Adil A., Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis // J Am Acad Dermatol. 2017. Vol. 77 (1). P.136–141.
9. Orfanos C. E., Vogels L. Local therapy of androgenetic alopecia with 17 alpha-estradiol. A controlled, randomized double-blind study (author’s transl) // Dermatologica. 1980. Vol. 161 (2). P.124–132.
10. Li Z. J., Choi H. I., Choi D. K. et al. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth // Dermatol Surg. 2012. Vol. 38 (7 Pt. 1). P.1040–1046.
11. Leavitt M., Perez-Meza D., Rao N. A. et al. Effects of finasteride (1 mg) on hair transplant // Dermatol Surg. 2005. Vol. 31 (10). P.1268–1276.
12. Jain N., Doshi B., Khopkar U. Trichoscopy in Alopecias: Diagnosis Simplified // Int J Trichology. 2013. Vol. 5 (4). P.170–178.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
